Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects

Taysha Gene Therapies Inc. (TSHA) is a biotech company developing a gene therapy for Rett syndrome. The company has begun dosing patients in the REVELA pivotal trial and expects to complete dosing in both REVEAL and ASPIRE trials in Q2. Jefferies has reiterated Taysha Gene Therapies as a promising biotech company, expecting significant growth in 2026 and potential peak revenue of $2 billion.